From Pulse 2.0 · Amit Chowdhry · · 1m
Galvanize Therapeutics Raises $130 Million Series D
Galvanize Therapeutics secures $130M Series D to expand pulsed electric field ablation platform.
In brief
Galvanize Therapeutics secures $130M Series D to expand pulsed electric field ablation platform. Galvanize Therapeutics raised $130 million in Series D funding to commercialize its Aliya pulsed electric field platform and develop new applications in oncology and chronic disease. Originally reported by Pulse 2.0.
Funding Round
Galvanize Therapeutics closed an oversubscribed $130 million Series D financing to expand commercial business, generate clinical evidence, and develop pulsed electric field technologies.
Investors
HealthQuest Capital led the round with Olympus Innovation Ventures and Braidwell joining existing backers including Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research…
Leadership
HealthQuest Founder and Managing Partner Dr. Garheng Kong will join Galvanize’s board to support the company’s growth strategy.
Commercial Progress
The company commercializes its Aliya pulsed electric field platform in the United States while developing applications in oncology and chronic disease.
What matters most
Galvanize Therapeutics raised $130 million in Series D funding to commercialize its Aliya pulsed electric field platform and develop new applications in oncology and chronic disease.
Read the TL;DR — this story on one card.

